Table 5:

Base case and scenario analyses

StrategyCostIncremental Cost ($)Effectiveness (QALYs)Incremental EffectivenessIncremental Cost-EffectivenessICER
Base case
    CEA$24,6246.833605
    CAS$30,731$6107.006.71−0.124580Dominateda
SAPPHIRE
    CEA$77,377$14,801.485.14−1.9615049Dominateda
    CAS$62,5767.18814
EVA-3S
    CEA$225856.82$3312
    CAS$30,832$8246.386.67−0.15$4695Dominateda
CREST
    CEA$22,2596.89$3227
    CAS$25,846$3587.006.63−0.27$3900Dominateda
  • Note:—ICER indicates incremental cost-effectiveness ratio.

  • a “Dominated” means that the treatment modality was associated with more cost and less effectiveness.